{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    10,
    11,
    12,
    16,
    17,
    20,
    21,
    37,
    38,
    40,
    49,
    51,
    55
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "COVID-19 Procedure Modifications",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.5, 5.3.1.1, 5.4.1, 5.7, 6.1.6, 9.2, 9.3",
        "sectionTitle": "Benefits and Risks / Study Procedures",
        "description": "References to updated study procedures in the context of the COVID-19 pandemic"
      },
      {
        "id": "ref_2",
        "name": "Off-site Phone Visit Options",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1, 5.3.1.1, Appendix F",
        "sectionTitle": "Overall Study Design / Study Procedures",
        "description": "References to the introduction of off-site phone visits for stable subjects"
      },
      {
        "id": "ref_3",
        "name": "Tumor Assessment Schedule",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3.1.1, Appendix C, D, E",
        "sectionTitle": "Study Procedures",
        "description": "References for additional tumor assessment schedule details"
      },
      {
        "id": "ref_4",
        "name": "IDMC Review Updates",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3.5, 8.1.8",
        "sectionTitle": "Safety Variables / IDMC",
        "description": "References to updated Independent Data Monitoring Committee review language"
      },
      {
        "id": "ref_5",
        "name": "Chemotherapy Guidelines",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.7.1.1",
        "sectionTitle": "Investigational Plan",
        "description": "Reference to guidelines on when chemotherapy can begin based on hematologic counts"
      },
      {
        "id": "ref_6",
        "name": "Adverse Event Reporting",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.1.5",
        "sectionTitle": "Adverse Event Reporting",
        "description": "Reference to reporting of MDS, AML, or secondary primary malignancies"
      },
      {
        "id": "ref_7",
        "name": "Contact Information",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.0",
        "sectionTitle": "Protocol Deviations and Safety Reporting",
        "description": "Reference for AbbVie TA MD contact information"
      },
      {
        "id": "ref_8",
        "name": "HER2 Testing Guidelines",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix K",
        "sectionTitle": "ASCO-CAP HER2 Test Guideline Recommendations",
        "description": "Reference for HER2-negative definition criteria"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "AbbVie*",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 1
      },
      {
        "id": "annot_2",
        "text": "Discussion with the AbbVie TA MD may be needed prior to unblinding and crossover to verify that criteria for unequivocal PD are met.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Optional Unblinded Veliparib Monotherapy Treatment (Crossover)",
        "pageNumber": 38
      },
      {
        "id": "annot_3",
        "text": "Locally advanced breast cancer must not be primarily amenable to surgical resection or radiation with curative intent.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Main Inclusion",
        "pageNumber": 7
      },
      {
        "id": "annot_4",
        "text": "Subjects with BRCA variants of uncertain significance or polymorphisms in BRCA1 or BRCA2 will not be eligible for the study.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Main Inclusion",
        "pageNumber": 8
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Amendment 4",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-07-23",
        "description": "Incorporating Administrative Changes 1, 2, 3, and 4 and Amendments 1, 2, 3, and 4",
        "amendmentNumber": "4"
      },
      {
        "id": "ver_2",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2014-03-17",
        "description": "Original Protocol",
        "amendmentNumber": "0"
      },
      {
        "id": "ver_3",
        "versionNumber": "Amendment 3",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-06-17",
        "description": "Previous Protocol Version",
        "amendmentNumber": "3"
      }
    ],
    "summary": {
      "referenceCount": 8,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}